J&J’s Cardiovascular Unit Stands Out Again in Q1

Why It Matters

The pivot positions J&J to capture higher‑margin, faster‑growing revenue streams while shedding slower‑growth assets, reshaping its earnings trajectory and appealing to investors seeking stronger medtech exposure.

Key Takeaways

• Cardiovascular unit posted 13% growth, $2.38 billion Q1 sales.
• Abiomed revenue rose 16.3% to $488 million; Shockwave up 18.5% to $305 million.
• Medtech overall grew 7.7% YoY, driven by high‑margin cardiovascular acquisitions.
• J&J plans orthopedics spin‑off, shifting focus to faster‑growing medtech.
• Targeted growth to shift from mid‑single‑digit to high‑single‑digit rates.

Pulse Analysis

Johnson & Johnson’s medtech division is accelerating a strategic pivot toward high‑growth therapeutic areas, leaving slower‑growing orthopedics behind. Over the past several years the company has invested roughly $30 billion in cardiovascular platforms, most notably the 2023 acquisitions of Abiomed, a leader in mechanical circulatory support, and Shockwave, a pioneer in intravascular lithotripsy. These deals have expanded J&J’s product portfolio into mechanical heart pumps and advanced plaque‑modifying technologies, positioning the firm to capture premium pricing and recurring revenue streams that outpace traditional implant markets. Cross‑selling across J&J’s global network should boost adoption rates.

In the first quarter of 2026 the cardiovascular segment delivered $2.38 billion in sales, a 13% year‑over‑year increase that eclipsed the single‑digit growth seen in J&J’s surgery, vision and orthopedics units. Abiomed’s revenue climbed 16.3% to $488 million, while Shockwave posted an 18.5% rise to $305 million, underscoring the profitability of the recent acquisitions. The broader medtech business posted 7.7% growth to $8.64 billion, but the company’s leadership signaled a shift from mid‑single‑digit to high‑single‑digit growth targets, prompting the planned spin‑off of the multibillion‑dollar orthopedics franchise. If trends hold, the unit may exceed $3 billion annual sales by 2028.

The renewed emphasis on cardiovascular and surgical‑robotics technologies aligns J&J with a wave of payer‑friendly, minimally invasive solutions that are reshaping hospital procurement cycles. Competitors such as Medtronic and Abbott are also expanding their cardiac portfolios, intensifying the race for market share in high‑margin segments like mechanical circulatory support and intravascular lithotripsy. For investors, the clear growth trajectory and the upcoming orthopedics divestiture reduce exposure to low‑growth assets while unlocking capital that can be redeployed into next‑generation medtech innovations, supporting a higher earnings outlook. The move aims to tap a $150 billion market by 2030.